A Win for Gene-Altering Therapy

What Does the FDA Panel's Endorsement of Gene Therapy Mean for Myeloma Patients?

On Wednesday, an advisory panel convened by the US Food and Drug Administration (FDA) voted unanimously to recommend the approval of therapy that genetically alters patients’ own cells to treat children and young adults with late-stage leukemia. The groundbreaking approach holds great promise, but also poses some serious risks, especially when used to treat multiple myeloma, says IMF Chairman Dr. Brian Durie. Read Dr. Durie's blog.

Research News Roundup: Promising Kyprolis Results, Another FDA Approval, Launch of a New Collaboration 

This was a busy week in the world of cancer research. Amgen announced promising follow-up results from the ASPIRE trial, in which KRd (Kyprolis®, Revlimid®, and dexamethasone) has produced a median overall survival of 48.3 months versus Rd’s 40.4 months for patients in the first relapse setting. “This is clearly an important survival advantage,” notes IMF Chairman Dr. Brian Durie.“ In the earlier ENDEAVOR trial, Kyprolis showed superiority versus Velcade® (another proteasome inhibitor) in the relapse setting as well.” Both studies provide evidence of the added value of Kyprolis.” More research news.

 

Tune in Today: Myeloma Updates 2017 Webinar: Best of ASCO/EHA/IMWG

Today at 4:00 PM PT / 7:00 PM ET, Dr. Brian Durie explains exciting current trends in myeloma treatment and research during a Myeloma Updates 2017 webinar. This webinar features updates from the three major medical meetings held in June 2017 – the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG). Register for FREE now for this webinar that includes a Q&A Session

 

Watch This Video on the Use of Minimal Residual Disease (MRD) Testing in Clinical Trials

During the International Myeloma Working Group annual meeting in Madrid, Spain, leading myeloma experts discussed six topline questions in the field of myeloma. Here is one of the questions from that meeting: Can MRD testing in trials guide decisions? View more IMWG videos.

Calling All Researchers: Submit Your Grant Applications!

The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The grants are awarded to researchers in the field of multiple myeloma and related disorders including SMM (smoldering multiple myeloma), MGUS (monoclonal gammopathy of undetermined significance), and immunoglobulin-derived amyloidosis. The 2018 grants will fund senior research projects with $80,000 and junior research projects with $50,000. Tuesday, August 1st, 2017, is the deadline for applications.

 

What exactly is high-risk myeloma, and how should it be treated?

In this week’s video, Dr. Brian Durie discusses why the ideal therapy for high-risk myeloma is still unknown, but presents options for treatment.

 

 


We Thank Our Sponsors: Amgen, Celgene Corporation, Genentech, Janssen Pharmaceuticals, and Takeda Oncology